Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats

被引:60
作者
Hammerbeck, David M.
Burleson, Gary R.
Schuller, Craig J.
Vasilakos, John P.
Tomai, Mark
Egging, Elaine
Cochran, Felicia R.
Woulfe, Susan
Miller, Richard L.
机构
[1] 3M Pharmaceut, Dept Pharmacol, M Ctr 3, St Paul, MN 55144 USA
[2] Burleson Res Technol Inc, Morrisville, NC 27560 USA
关键词
toll-like receptor; influenza; innate immunity; interferon; cytokine;
D O I
10.1016/j.antiviral.2006.07.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Toll-like receptors (TLR) detect conserved molecular patterns expressed by pathogens. Detection of the "molecular signature" for RNA viruses including influenza has been attributed to TLR3, TLR7, and TLR8. In the present study, compound 3M-011 was shown to be a synthetic human TLR7/8 agonist and cytokine inducer. 3M-011 was investigated as a stand-alone immune response modifier in a rat model of human influenza. Intranasal (IN) administration of 3M-011 significantly inhibited H3N2 influenza viral replication in the nasal cavity when administered from 72 It before IN viral inoculation to 6 h after inoculation. Viral inhibition correlated with the ability of the TLR7/8 agonist to stimulate type I interferon (IFN) and other cytokines such as tumor necrosis factor-alpha, interleukin-12, and IFN-gamma from rat peripheral blood mononuclear cells. Prophylactic administration of TLR7/8 agonist also suppressed influenza viral titers in the lung, which corresponded with local IFN production. The activity of the TLR7/8 agonist resulted in greater inhibition of viral titers compared to rat recombinant IFN-alpha administered in a comparable dosing regimen. These studies indicate that TLR7/8 agonists may have prophylactic and therapeutic benefits in the treatment of respiratory viral infections, such as influenza. when administered prior to or shortly after viral inoculation. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 65 条
[1]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[2]   Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity [J].
Arulanandam, BP ;
O'Toole, M ;
Metzger, DW .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) :940-949
[3]   Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines [J].
Arulanandam, BP ;
Mittler, JN ;
Lee, WT ;
O'Toole, M ;
Metzger, DW .
JOURNAL OF IMMUNOLOGY, 2000, 164 (07) :3698-3704
[4]   THE TRANSMUCOSAL ABSORPTION OF RECOMBINANT HUMAN INTERFERON-ALPHA B/D HYBRID IN THE RAT AND RABBIT [J].
BAYLEY, D ;
TEMPLE, C ;
CLAY, V ;
STEWARD, A ;
LOWTHER, N .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (09) :721-724
[5]   Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment [J].
Bernstein, DI ;
Harrison, CJ ;
Tomai, MA ;
Miller, RL .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (06) :844-849
[6]   IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro [J].
Bhardwaj, N ;
Seder, RA ;
Reddy, A ;
Feldman, MV .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (03) :715-722
[7]  
Brammer T Lynnette, 2002, MMWR Surveill Summ, V51, P1
[8]   Models of respiratory immunotoxicology and host resistance [J].
Burleson, GR .
IMMUNOPHARMACOLOGY, 2000, 48 (03) :315-318
[9]  
BURLESON GR, 1995, METHODS IMMUNOTOXICO, V2, P181
[10]  
BURLESON GR, 1995, METHODS IMMUNOTOXICO, V2, P345